We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
-0.86%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$272M
AUM Growth
-$70.2M
Cap. Flow
-$30.4M
Cap. Flow %
-11.2%
Top 10 Hldgs %
40.84%
Holding
92
New
12
Increased
37
Reduced
27
Closed
16

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$8.78M
2
WAT icon
Waters Corp
WAT
+$8.33M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$6.57M
4
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$4.23M
5
UTHR icon
United Therapeutics
UTHR
+$3.6M

Top Sells

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$7.76M
2
ABBV icon
AbbVie
ABBV
+$7.41M
3
IDXX icon
Idexx Laboratories
IDXX
+$5.14M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$5.09M
5
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$4.87M

Sector Composition

Rank Sector Weight
1 Healthcare 96.48%
2 Industrials 1.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SDGR icon
26
Schrodinger
SDGR
$1.39B
$3.23M 1.19%
122,225
+6,334
+5% +$170K
ANIP icon
27
ANI Pharmaceuticals
ANIP
$1.71B
$3.22M 1.19%
108,559
+648
+0.6% +$18.7K
ACLX
28
DELISTED
Arcellx
ACLX
$3.22M 1.19%
+178,000
New +$2.3M
PRCT icon
29
Procept Biorobotics
PRCT
$1.23B
$3.09M 1.14%
+94,500
New +$3.44M
MASS icon
30
908 Devices
MASS
$401M
$3.07M 1.13%
149,315
-25,685
-15% -$432K
PODD icon
31
Insulet
PODD
$9.99B
$3.03M 1.11%
13,889
+1,218
+10% +$277K
ALNY icon
32
Alnylam Pharmaceuticals
ALNY
$29.9B
$3.02M 1.11%
20,734
-33,274
-62% -$4.72M
MNKD icon
33
MannKind Corp
MNKD
$1.25B
$2.91M 1.07%
764,814
+89,411
+13% +$328K
PHLT
34
DELISTED
Performant Healthcare Inc
PHLT
$2.66M 0.98%
1,011,324
+54,241
+6% +$135K
NTRA icon
35
Natera
NTRA
$45.2B
$2.62M 0.97%
74,047
-55,897
-43% -$2.07M
COGT icon
36
Cogent Biosciences
COGT
$6.6B
$2.6M 0.96%
+288,750
New +$1.97M
DXCM icon
37
DexCom
DXCM
$34.2B
$2.6M 0.96%
34,834
-16,114
-32% -$1.47M
SUPN icon
38
Supernus Pharmaceuticals
SUPN
$2.71B
$2.56M 0.94%
88,658
-20,296
-19% -$581K
AKYA
39
DELISTED
Akoya BioSciences
AKYA
$2.37M 0.87%
184,785
+34,464
+23% +$357K
APEN
40
DELISTED
Apollo Endosurgery, Inc.
APEN
$2.37M 0.87%
650,000
-160,411
-20% -$758K
IMUX icon
41
Immunic
IMUX
$211M
$2.26M 0.83%
65,003
-43,922
-40% -$2.81M
CDXS icon
42
Codexis
CDXS
$173M
$2.13M 0.79%
204,049
-64,095
-24% -$804K
DAWN
43
DELISTED
Day One Biopharmaceuticals
DAWN
$2.05M 0.76%
+114,750
New +$1.18M
IMGO
44
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
$1.97M 0.73%
147,387
+7,636
+5% +$121K
KRMD icon
45
KORU Medical Systems
KRMD
$155M
$1.71M 0.63%
675,434
+2,977
+0.4% +$7.22K
HAE icon
46
Haemonetics
HAE
$4.07B
$1.63M 0.6%
+25,000
New +$1.48M
RXST icon
47
RxSight
RXST
$289M
$1.62M 0.6%
+115,000
New +$1.52M
AXGN icon
48
Axogen
AXGN
$2.64B
$1.54M 0.57%
188,494
+59,547
+46% +$509K
MDGL icon
49
Madrigal Pharmaceuticals
MDGL
$12.4B
$1.53M 0.56%
21,336
+1,106
+5% +$81.3K
VCYT icon
50
Veracyte
VCYT
$3.64B
$1.47M 0.54%
73,966
+13,315
+22% +$269K
1
2
3 4

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q2 2022 Portfolio in Review

As of Q2 2022, Parkman Healthcare Partners held 92 positions worth $272M, down 21% from $342M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Parkman Healthcare Partners withdrew a net $30.4M in Q2 2022, closing 16 positions and reducing 27 holdings. Its most notable exit was BioCryst Pharmaceuticals, an estimated $7.76M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Industrials.

Against the trend, Parkman Healthcare Partners opened a new position in Elevance Health worth $8.57M.

  • Parkman Healthcare Partners's largest Q2 2022 buy was Elevance Health: 17,750 shares worth $8.57M.
  • Parkman Healthcare Partners added most to CTI BioPharma Corp. (DE) Common Stock in Q2 2022, an estimated $4.23M increase.
  • Parkman Healthcare Partners's biggest Q2 2022 reduction was Aclaris Therapeutics, cutting an estimated $5.09M.
  • Parkman Healthcare Partners fully exited BioCryst Pharmaceuticals in Q2 2022, selling an estimated $7.76M.
  • Parkman Healthcare Partners's ten largest holdings make up 41% of its $272M portfolio in Q2 2022.
  • Parkman Healthcare Partners opened 12 new positions and closed 16 in Q2 2022.
  • Parkman Healthcare Partners's portfolio value fell 21% quarter-over-quarter to $272M.

Based on Parkman Healthcare Partners's 13F filing for Q2 2022, filed 12 Aug 2022.